ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2010
Imaging of beta-cell mass and function.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes.Molecular imaging and biology · 2016Trial
- Pancreatic β-cell Dysfunction and Diabetes.Juntendo medical journal · 2025Review
- Illuminating the complete ß-cell mass of the human pancreas- signifying a new view on the islets of Langerhans.Nature communications · 2024Article
- Hyperbaric oxygen treatment improves pancreatic β‑cell function and hepatic gluconeogenesis in STZ‑induced type‑2 diabetes mellitus model mice.Molecular medicine reports · 2022Article
- Optoacoustic imaging in endocrinology and metabolism.Nature reviews. Endocrinology · 2021Review
- Zinc-Chelating Small Molecules Preferentially Accumulate and Function within Pancreatic β Cells.Cell chemical biology · 2019Article
- Molecular imaging of β-cells: diabetes and beyond.Advanced drug delivery reviews · 2019Review
- Futility of attempts to detect and quantify beta cells by PET imaging in the pancreas: why it is time to abandon the approach.Diabetologia · 2018Review
- Failed PET Application Attempts in the Past, Can We Avoid Them in the Future?Molecular imaging and biology · 2016Article
- Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.Pharmacological reviews · 2016Review
- Deletion of β-Arrestin2 in Mice Limited Pancreatic β-Cell Expansion under Metabolic Stress through Activation of the JNK Pathway.Molecular medicine (Cambridge, Mass.) · 2016Article
- Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging.Molecular imaging and biology · 2016Article
- β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.World journal of diabetes · 2015Review
- Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.Journal of medicinal chemistry · 2015Article
- Autonomous molecular cascades for evaluation of cell surfaces.Nature nanotechnology · 2013Article
- Article
- Beta-cell imaging: call for evidence-based and scientific approach.Molecular imaging and biology · 2013Review
- β-Cell mass imaging with DTBZ positron emission tomography: is it possible?Molecular imaging and biology · 2013Article
- Localization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease.Advances in pharmacology (San Diego, Calif.) · 2013Review
- Neurofunctional imaging of β-cell dynamics.Diabetes, obesity & metabolism · 2012Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
In both type 1 and type 2 diabetes mellitus, beta-cell mass (BCM), which exclusively produces insulin, is lost. Various therapeutic strategies are being developed that target BCM to restore its function by promoting beta-cell neogenesis and regeneration or by preventing its apoptosis. To this end, it is essential to identify biomarkers of BCM. Of the various imaging platforms, radionuclide-based imaging methods using radioligands that directly target BCM appear promising. In particular, the vesicular monoamine transporter type 2 (VMAT2), which is expressed almost exclusively by beta-cells and found in close association with insulin, can be noninvasively imaged with PET and (11)C-dihydrotetrabenazine or its derivatives. Despite the major limitation that beta-cells are low in abundance (1%-2%) and dispersed throughout the pancreas, VMAT2 PET is sensitive enough to detect VMAT2 signal and to allow kinetic model-based quantification of VMAT2 binding within the pancreas. However, these techniques are still in early stages, and careful further evaluations and technical developments are needed before they can be clinically used as a valid biomarker of BCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.